Jan 26, 2023 04:05PM
Nov 14, 2022 07:35AM
Oct 27, 2022 12:52PM
Oct 26, 2022 08:30AM
Oct 24, 2022 05:54AM
Oct 23, 2022 11:36PM
Oct 23, 2022 11:36PM Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement
Oct 23, 2022 11:30PM
Oct 18, 2022 04:30PM
Oct 14, 2022 10:02AM
Oct 14, 2022 06:45AM
Oct 3, 2022 05:52AM
Oct 2, 2022 07:36PM
Oct 2, 2022 07:36PM Myovant Sciences Special Committee of Board Confirms Receipt of Preliminary, Non-binding Proposal from Sumitovant Biopharma and Sumitomo Pharma to Acquire Remaining Shares
Sep 16, 2022 04:30PM
Sep 16, 2022 10:37AM
Sep 8, 2022 10:05AM
Sep 7, 2022 10:03AM
Sep 2, 2022 06:45AM
Aug 16, 2022 04:30PM
Aug 5, 2022 08:50PM Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE®, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
Aug 5, 2022 08:50PM
Jul 27, 2022 04:05PM
Jul 27, 2022 04:05PM
Jul 18, 2022 04:30PM
Jul 13, 2022 11:02AM
Jul 13, 2022 06:45AM
Jul 7, 2022 11:07AM Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County
Jul 5, 2022 08:05AM
Jun 27, 2022 08:00AM
Jun 27, 2022 08:00AM
Jun 17, 2022 06:46AM
Jun 17, 2022 06:45AM
Jun 17, 2022 06:45AM
Jun 16, 2022 04:35PM Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Jun 7, 2022 07:30AM
Jun 3, 2022 06:50AM
Jun 2, 2022 06:51AM
Jun 2, 2022 06:50AM
Jun 2, 2022 06:50AM
May 16, 2022 09:00AM
May 15, 2022 10:05AM Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
May 13, 2022 12:33PM
May 10, 2022 08:00AM
May 10, 2022 08:00AM
May 10, 2022 06:55AM
May 10, 2022 06:55AM
May 9, 2022 06:30AM
May 9, 2022 06:30AM Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX® for Advanced Hormone-Sensitive Prostate Cancer in Europe
May 9, 2022 06:30AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All